Skip to main content

Advertisement

Log in

A Prospective Study of Patient Reported Outcomes in Pancreatic and Peri-ampullary Malignancy

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

The purpose of the present study was to describe the impact of treatment of pancreatic and peri-ampullary malignancy on patient reported outcomes (PRO). However, limited data are available describing the impact of curative or palliative therapy on pancreatic/peri-ampullary malignancy and quality of life.

Methods

Patients selected for pancreaticoduodenectomy (PD) completed the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire pre-surgery and 6 weeks, 3, 6, 12, 18, and 24 months postoperatively. Patients selected for palliative treatments completed the same questionnaire before treatment and monthly thereafter. Mean scores and 95 % confidence intervals (CI) were calculated for functional scales. Symptom scales and single items were categorized as either minimal or severe, and they were reported as proportions of patients experiencing severe symptoms with 95 % CI.

Results

A total of 100 patients (53 planned PD, 47 palliative) were enrolled. Of the 53 patients planned for surgery, 12 had tumors that were unresectable and 41 underwent pancreatoduodenectomy (PD). Seven patients were excluded because of benign histology or concurrent malignancy. Baseline questionnaire compliance was 70 %. For those undergoing PD, there were 53 complications, 7 deaths at 1 year, and 14 deaths at 2 years. Post-surgery most functions and symptoms deteriorated. Recovery in global health and most symptoms occurred by 3 months, and functional scales recovered by 6 months. Recovery of PRO was maintained in the survivors at 2 years. Palliative patients had poorer function and more symptoms at baseline; however, poor follow-up questionnaire compliance prevented further analysis of this group.

Conclusions

Pancreaticoduodenectomy has a short-term negative impact on PRO that recovers within 6 months and is maintained at 2 years in survivors. Further work evaluating palliative and curative treatment in larger patient groups with disease-specific questionnaires is necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cancer Research UK (2010) Pancreatic cancer incidence statistics, London, Cancer Research UK

  2. Cascinu S, Falconi M, Valentini V et al (2010) Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v55–v58

    Article  PubMed  Google Scholar 

  3. Weber A, Mittermeyer T, Wagenpfeil S et al (2009) Self-expanding metal stents versus polyethylene stents for palliative treatment in patients with advanced pancreatic cancer. Pancreas 38:e7–e12

    Article  PubMed  CAS  Google Scholar 

  4. Mossner J (2010) What’s new in therapy of pancreatic cancer? Dig Dis 28:679–683

    Article  PubMed  Google Scholar 

  5. Moss RA, Lee C (2010) Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther 3:111–127

    Article  PubMed  CAS  Google Scholar 

  6. Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection. J Am Med Assoc 304:1073–1081

    Article  CAS  Google Scholar 

  7. Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210

    Article  PubMed  CAS  Google Scholar 

  8. Hernandez JM, Morton CA, Al-Saadi S (2010) The natural history of resected pancreatic cancer without adjuvant chemotherapy. Am Surg 76:480–485

    PubMed  Google Scholar 

  9. Wilkowski R, Thoma M, Bruns C et al (2006) Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. J Pancreas 7:34–40

    Google Scholar 

  10. Blazeby JM, Avery K, Sprangers M et al (2006) Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol 24:3178–3186

    Article  PubMed  Google Scholar 

  11. Ohtsuka T, Yamaguchi K, Ohuchida J et al (2003) Comparison of quality of life after pylorus-preserving pancreatoduodenectomy and Whipple resection. Hepatogastroenterology 50:846–850

    PubMed  Google Scholar 

  12. Huang JJ, Yeo CJ, Sohn TA et al (2000) Quality of life and outcomes after pancreaticoduodenectomy. Ann Surg 231:890–898

    Article  PubMed  CAS  Google Scholar 

  13. Shaw CM, O’Hanlon DM, McEntee GP (2005) Long-term quality of life following pancreaticoduodenectomy. Hepatogastroenterology 52:927–932

    PubMed  Google Scholar 

  14. Ong HS, Ng EH, Heng G et al (2000) Pancreaticoduodenectomy with pancreaticogastrostomy: assessment of patients’ nutritional status, quality of life and pancreatic exocrine function. Aust N Z J Surg 70:199–203

    Article  PubMed  CAS  Google Scholar 

  15. Kostro J, Sledzinski Z (2008) Quality of life after surgical treatment of pancreatic cancer. Acta Chir Belg 108:679–684

    PubMed  CAS  Google Scholar 

  16. Labori KJ, Hjermstad MJ, Wester T et al (2006) Symptom profiles and palliative care in advanced pancreatic cancer: a prospective study. Support Care Cancer 14:1126–1133

    Article  PubMed  Google Scholar 

  17. Scheingraber S, Scheingraber T, Brauckhoff M et al (2005) Comparison between a general and a disease-specific health-related quality-of-life questionnaire in patients after pancreatic surgery. J Hepatobiliary Pancreat Surg 12:290–297

    Article  PubMed  Google Scholar 

  18. Patti MG, Pellegrini CA, Way LW (1987) Gastric emptying and small bowel transit of solid food after pylorus-preserving pancreaticoduodenectomy. Arch Surg 122:528–532

    Article  PubMed  CAS  Google Scholar 

  19. Fink AS, DeSouza LR, Mayer EA et al (1988) Long-term evaluation of pylorus preservation during pancreaticoduodenectomy. World J Surg 12:663–670. doi:10.1007/BF01655880

    Article  PubMed  CAS  Google Scholar 

  20. You YN, Thompson GB, Young WF Jr et al (2007) Pancreatoduodenal surgery in patients with multiple endocrine neoplasia type 1: operative outcomes, long-term function, and quality of life. Surgery 142:829–836 Discussion 836

    Article  PubMed  Google Scholar 

  21. Witzigmann H, Max D, Uhlmann D et al (2002) Quality of life in chronic pancreatitis: a prospective trial comparing classical Whipple procedure and duodenum-preserving pancreatic head resection. J Gastrointest Surg 6:173–179 Discussion 179–180

    Article  PubMed  Google Scholar 

  22. Whipple A (1942) Present-day surgery of the pancreas. N Engl J Med 226:515–526

    Article  Google Scholar 

  23. Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376

    Article  PubMed  CAS  Google Scholar 

  24. Fayers P, Aaronson N, Bjordal K et al (2002) EORTC QLQ-C30 Scoring Manual. EORTC Publications, Brussels

    Google Scholar 

  25. Osoba D, Rodrigues G, Myles J et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144

    PubMed  CAS  Google Scholar 

  26. Fayers P, Machin D (2007) Quality of life: assessment, analysis and interpretation. John Wiley & Sons, Chichester

    Google Scholar 

  27. Pezzilli R, Falconi M, Zerbi A et al (2011) Clinical and patient-reported outcomes after pancreatoduodenectomy for different diseases: a follow-up study. Pancreas 40:938–945

    Article  PubMed  Google Scholar 

  28. Chan C, Franssen B, Dominguez I et al (2012) Impact on quality of life after pancreatoduodenectomy: a prospective study comparing preoperative and postoperative scores. J Gastrointest Surg 16:1341–1346

    Article  PubMed  Google Scholar 

  29. Schwartz CE, Bode R, Repucci N et al (2006) The clinical significance of adaptation to changing health: a meta-analysis of response shift. Qual Life Res 15:1533–1550

    Article  PubMed  Google Scholar 

  30. Nordin K, Steel J, Hoffman K et al (2001) Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients. Br J Cancer 85:1265–1272

    Article  PubMed  CAS  Google Scholar 

  31. Fitzsimmons D, Johnson CD, George S et al (1999) Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer 35:939–941

    Article  PubMed  CAS  Google Scholar 

  32. National Cancer Institute (2006) The NCI Strategic plan for leading the nation to eliminate the suffering and death due to cancer. US Department of Health and Human Services National Institutes of Health, Washington

  33. ASCO Health Services Research Outcomes Working Group (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 96:671–679

    Google Scholar 

  34. Epstein RM, Alper BS, Quill TE (2004) Communicating evidence for participatory decision making. J Am Med Assoc 291:2359–2366

    Article  CAS  Google Scholar 

  35. McNair AG, Brookes ST, Davis CR et al (2010) Communicating the results of randomized clinical trials: do patients understand multidimensional patient-reported outcomes? J Clin Oncol 28:738–743

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was funded in part by a personal MRC Clinician Scientist Award (J.M.B.), by the MRC Hub for Trials Methodology Research (ConDuCT) (R.M and J.M.B.), and by the (UK) National Institute of Health Research (J.R. and N.S.B.). The authors are grateful to Joanna Nicklin for collecting the PRO data used in this study and to the members of the Upper Gastrointestinal Multidisciplinary Team at University Hospitals Bristol NHS Foundation Trust.

Conflict of interest

None declared.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. R. E. Rees.

Additional information

J. R. E. Rees and R. C. Macefield contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rees, J.R.E., Macefield, R.C., Blencowe, N.S. et al. A Prospective Study of Patient Reported Outcomes in Pancreatic and Peri-ampullary Malignancy. World J Surg 37, 2443–2453 (2013). https://doi.org/10.1007/s00268-013-2104-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-013-2104-8

Keywords

Navigation